SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Edward W. Brooke Synthetic CCD

PatientEdward W. Brooke
Date of birth1942-10-26
IdentifiersMRN HR-ML014-SYN; SSN (made up) 000-14-5063
Document date2026-11-01
AuthorHoward Bellamy, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection. Concerns: Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospital; Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his family. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years)One tablet once dailyOral route2025-10-28activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-02-10activeS

Procedures

ProcedureDatesStatusEvidence
Diagnostic mammography of both breasts: 1.9 cm irregular, spiculated retroareolar mass in the right breast (BI-RADS 5); left breast with no mass or gynecomastia (BI-RADS 1)2025-09-16 to 2025-09-16completedS
Ultrasound of both breasts and both axillae: 1.8 cm irregular hypoechoic retroareolar mass in the right breast; one right axillary lymph node with a thickened cortex; left breast and left axilla normal2025-09-16 to 2025-09-16completedS
Ultrasound-guided core needle biopsy of the right breast mass and the right axillary node: invasive ductal carcinoma, grade 2; estrogen receptor 95 percent, progesterone receptor 80 percent, HER2 1+ (negative), Ki-67 15 percent; the node contains metastatic carcinoma2025-09-18 to 2025-09-18completedS
Bilateral mastectomy, at another hospital. Pathology: right breast, invasive ductal carcinoma 1.8 cm, grade 2, margins clear, no lymphovascular invasion; left breast, benign breast tissue2025-10-07 to 2025-10-07completedS
Right axillary lymph node dissection, at the same operation: 1 of 14 lymph nodes with a 4 mm metastasis, no extranodal extension; pT1c pN1a, stage IIA2025-10-07 to 2025-10-07completedS
Advance care planning conversation, about 20 minutes2026-10-13 to 2026-10-13completedS

Immunizations

DateVaccineStatusEvidence
2025-10-14High-dose influenza vaccine, 2025-2026 seasoncompletedS
2018-04-10Tdap vaccinecompletedS
2026-10-13High-dose influenza vaccine, 2026-2027 seasoncompletedS
2026-10-13Pneumococcal conjugate vaccine PCV20completedS
2026-10-13Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
September 2002Breast cancer of the right breast in a man, diagnosed after he noticed discomfort in the right breast; mammogram, sonogram, and needle biopsy; he had never had a chest examination by a doctor beforeD (CLM-0003)
2002Operation for breast cancer, reported as a double mastectomy, with removal of the lymph nodes on the right side, to which the cancer had spreadD (CLM-0004, CLM-0005)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospitalactiveS
Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his familyactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.8 on 2026-01-13; Leukocytes [#/volume] in Blood by Automated count 6.1 on 2026-01-13; Platelets [#/volume] in Blood by Automated count 214 on 2026-01-13; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-01-13; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-01-13; Creatinine [Mass/volume] in Serum or Plasma 1.04 on 2026-01-13; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 71 on 2026-01-13; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2026-01-13; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 2026-01-13; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 on 2026-01-13; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 76 on 2026-01-13; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 2026-01-13; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-01-13; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 on 2026-05-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-01-13; DXA Femur [T-score] Bone density -1.2 on 2026-02-10; DXA Lumbar spine [T-score] Bone density -0.4 on 2026-02-10; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-13; Total score [Mini-Cog] 5 on 2026-10-13; Total score [AUDIT-C] 0 on 2026-10-13; Cholesterol [Mass/volume] in Serum or Plasma 176 on 2026-10-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-10-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 104 on 2026-10-13; Triglyceride [Mass/volume] in Serum or Plasma 92 on 2026-10-13 [S]

Strengths and supports: Supports: family and a wide circle of friends and former colleagues [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast canceractiveconfirmed C50.121S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D).
Estrogen receptor-positive status of the breast canceractiveconfirmed Z17.0S — Synthetic receptor result; his tumor biology was not made public.
Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health reviewactiveconfirmed Z79.810S — Synthetic adjuvant therapy in the modern episode.
Absence of both breasts after bilateral mastectomyactiveconfirmed Z90.13S — The double mastectomy is reported publicly (D); the coding is synthetic.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-13Hemoglobin [Mass/volume] in Blood13.8g/dL13.2-16.6 g/dLNormalS
2026-01-13Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2026-01-13Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2026-01-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-01-13Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-01-13Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.74-1.35 mg/dLNormalS
2026-01-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M71mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-13Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
2026-01-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-55 U/LNormalS
2026-01-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L8-48 U/LNormalS
2026-01-13Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma76U/L40-129 U/LNormalS
2026-01-13Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-01-13Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-01-1325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mL30-100 ng/mLLowS
2026-01-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-02-10DXA Femur [T-score] Bone density-1.2{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2026-02-10DXA Lumbar spine [T-score] Bone density-0.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisNormalS
2026-02-10Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-05-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS
2026-05-12Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-08-11Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-13Total score [Mini-Cog]5{score}S
2026-10-13Total score [AUDIT-C]0{score}S
2026-10-13Cholesterol [Mass/volume] in Serum or Plasma176mg/dL<=200 mg/dLNormalS
2026-10-13Cholesterol in HDL [Mass/volume] in Serum or Plasma54mg/dL>=40 mg/dLNormalS
2026-10-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation104mg/dL<=129 mg/dLNormalS
2026-10-13Triglyceride [Mass/volume] in Serum or Plasma92mg/dL<=149 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-13Body height183cmS
2026-01-13Body weight81.6kgS
2026-01-13Body mass index (BMI) [Ratio]24.4kg/m2S
2026-01-13Systolic blood pressure134mm[Hg]S
2026-01-13Diastolic blood pressure76mm[Hg]S
2026-01-13Heart rate70/minS
2026-01-13Respiratory rate14/minS
2026-01-13Body temperature36.6CelS
2026-01-13Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-02-10Body height183cmS
2026-02-10Body weight81.8kgS
2026-02-10Body mass index (BMI) [Ratio]24.4kg/m2S
2026-02-10Systolic blood pressure130mm[Hg]S
2026-02-10Diastolic blood pressure74mm[Hg]S
2026-02-10Heart rate68/minS
2026-02-10Respiratory rate14/minS
2026-02-10Body temperature36.7CelS
2026-02-10Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-05-12Body height183cmS
2026-05-12Body weight82.2kgS
2026-05-12Body mass index (BMI) [Ratio]24.5kg/m2S
2026-05-12Systolic blood pressure128mm[Hg]S
2026-05-12Diastolic blood pressure74mm[Hg]S
2026-05-12Heart rate66/minS
2026-05-12Respiratory rate14/minS
2026-05-12Body temperature36.6CelS
2026-05-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-11Body height183cmS
2026-08-11Body weight82kgS
2026-08-11Body mass index (BMI) [Ratio]24.5kg/m2S
2026-08-11Systolic blood pressure128mm[Hg]S
2026-08-11Diastolic blood pressure72mm[Hg]S
2026-08-11Heart rate68/minS
2026-08-11Respiratory rate14/minS
2026-08-11Body temperature36.7CelS
2026-08-11Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-13Body height183cmS
2026-10-13Body weight82.4kgS
2026-10-13Body mass index (BMI) [Ratio]24.6kg/m2S
2026-10-13Systolic blood pressure130mm[Hg]S
2026-10-13Diastolic blood pressure74mm[Hg]S
2026-10-13Heart rate68/minS
2026-10-13Respiratory rate14/minS
2026-10-13Body temperature36.6CelS
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-01-13First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissectionfinishedS
2026-02-10Four-week follow-up with medical oncology consultation: adjuvant plan, germline testing, tamoxifen safety, and bone density resultsfinishedS
2026-05-12Three-month follow-up: germline result, tamoxifen side effects and adherence, vitamin D recheckfinishedS
2026-08-11Survivorship visit: cancer-related history and examination, tamoxifen review, and written survivorship care planfinishedS
2026-10-13Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Medical oncology consultation to take over adjuvant endocrine therapy, confirm that no further adjuvant treatment is needed, and arrange germline genetic testingcompletedGL-ASCO-MBC-2020, GL-NCCN-BREAST-2025S
Tamoxifen 20 mg daily for an initial five years, with venous thromboembolism symptoms, mood, hot flashes, sexual side effects, adherence, and interacting medicines reviewed at every visitcompletedGL-ASCO-MBC-2020, GL-CMID-2026S
Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), with a letter for first-degree relatives explaining the resultcompletedGL-ASCO-MBC-2020, GL-ASCO-SSO-GERM-2024S
Bone health: DXA at baseline, vitamin D repletion, dietary calcium, and weight-bearing exercise; bone-modifying drugs only for osteoporosis, not to prevent recurrencecompletedGL-ASCO-MBC-2020, GL-ASCO-BONE-2019, GL-CMID-2026S
Survivorship surveillance: cancer-related history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly; no routine imaging, blood tests, or tumor markers without symptoms; lymphedema checkscompletedGL-CMID-2026, GL-ACS-ASCO-SURV-2016, GL-ASCO-MBC-2020S
Distress screening at each visit, at least 150 minutes of activity a week, and a written survivorship care plancompletedGL-ACS-ASCO-SURV-2016, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Take tamoxifen every day with side effects managed, aiming to continue for at least five years2026-08-11completedNo missed doses by pill count over seven months; mild hot flashes and a mild fall in libido, both manageable; no clot symptomsS
Complete germline genetic testing with counseling, and give him written information for his relatives2026-05-12completedNo pathogenic variant in a multigene panel; family letter givenS
Establish bone health on hormone therapy at his age: DXA, vitamin D of 30 ng/mL or more, and weight-bearing exercise2026-05-12completedFemoral neck T-score -1.2; vitamin D 36 ng/mL after supplementationS
Give a written survivorship care plan with the surveillance schedule2026-08-11completedSurvivorship care plan given at the survivorship visitS

Functional Status

Mental Status